Verbal memory impairment in
schizophrenia is associated with abnormalities in
gamma-aminobutyric acid (
GABA)-ergic and
brain-derived neurotrophic factor (
BDNF) systems. Recent evidence from animal and clinical studies that adding
fluvoxamine to
antipsychotics alters the expression of transcripts encoding for the
GABA-A receptor and
BDNF led us to postulate that
fluvoxamine augmentation may improve memory in
schizophrenia. To test this, we examined the effect of add-on
fluvoxamine on verbal memory and other cognitive functions and related it to the expression of
mRNA coding for the
GABA-A receptor and
BDNF in peripheral mononuclear cells (PMC) of schizophrenic patients. Twenty-nine patients completed a 6-week study in which
fluvoxamine (100 mg/day) was added to ongoing
antipsychotic treatment. Verbal memory, abstraction working memory, object and face recognition, and psychomotor speed and clinical symptoms were assessed at baseline and after 3 and 6 weeks of treatment. Blood samples were taken at baseline and weeks 1, 3, and 6 and PMC was assayed for the
GABA-A beta3 receptor and
BDNF mRNA by quantitative real-time reverse transcription-PCR. Associative and logical verbal memory improved significantly and showed a significant correlation with changes in PMC
BDNF and
GABA-A beta3 receptor
mRNA, which increased during treatment. Abstraction and object recognition improved, but this did not correlate with PMC measures. Negative and positive symptoms improved significantly; the latter showed significant correlations with changes in PMC measures. Addition of
fluvoxamine to
antipsychotics improves verbal memory. It is postulated that the mechanism involves enhanced
GABA-A receptor/
BDNF-dependent synaptic plasticity in the hippocampus.